Sugi Predict

Sugi Predict / Compounds / SCHEMBL835266

SCHEMBL835266

SCHEMBL835266

CC1CCN(CC(=O)O)CC1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.50
▸ HSD17B10 Q99714 1/20 0.48
▸ ALDH1A1 P00352 7/20 0.47
▸ POLB P06746 1/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ NPC1 O15118 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.43
▸ LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1375997 0.98 HTT (0.49) HTTHSD17B10ALDH1A1POLBSMN1; SMN2
SCHEMBL21675650 0.91 HSD17B10 (0.45) HTTHSD17B10ALDH1A1POLBSMN1; SMN2
SCHEMBL2557014 0.87 L3MBTL1 (0.42) HTTHSD17B10ALDH1A1POLBRAB9A
Acetic Acid SCHEMBL27412329 0.84 L3MBTL1 (0.40) HTTHSD17B10ALDH1A1POLBRAB9A
SCHEMBL12640327 0.82 ALDH1A1 (0.47) HTTALDH1A1POLBSMN1; SMN2RAB9A
SCHEMBL15363579 0.81 ACHE (0.47) HTTHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL27159946 0.80 ALDH1A1 (0.49) HTTALDH1A1POLBSMN1; SMN2RAB9A
SCHEMBL11265 0.80 KDM4E (0.52) HTTALDH1A1POLBSMN1; SMN2RAB9A
SCHEMBL23291292 0.79 HSD17B10 (0.56) HSD17B10ALDH1A1KDM4E
SCHEMBL167007 0.79 HSD17B10 (0.50) HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4330689-A2 CHIMERIC ABC TRANSPORTERS AND SCREENING METHODS Genentech, Inc. (US) 2024-03-06 — — EP disclosed
CN-117203529-A Chimeric ABC transporter and screening method 基因泰克公司 2023-12-08 — — CN disclosed
US-20230278989-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM ASTEX THERAPEUTICS LIMITED (GB) 2023-09-07 — — US disclosed
US-20230278989-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM ASTEX THERAPEUTICS LIMITED (GB) 2023-09-07 — — US disclosed
US-20230240960-A1 COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT ODDITY LABS, LLC 2023-08-03 — — US disclosed
WO-2023133240-A1 COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT REVELA, INC. (US) 2023-07-13 — — WO disclosed
US-20230139056-A1 METHODS, COMPOSITIONS AND REAGENTS FOR PREPARING COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2023-05-04 — — US disclosed
US-20230139056-A1 METHODS, COMPOSITIONS AND REAGENTS FOR PREPARING COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2023-05-04 — — US disclosed
EP-3258925-B1 METHODS AND COMPOSITIONS FOR DECREASING GASTRIC EMPTYING PURDUE PHARMA LP (US) 2023-03-29 — — EP disclosed
WO-2022232125-A2 CHIMERIC ABC TRANSPORTERS AND SCREENING METHODS GENENTECH, INC. (US) 2022-11-03 — — WO disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 — — US disclosed
CN-1726192-A 3-amino-piperidine derivatives and process for preparing same PFIZER (US) 2006-01-25 — — CN disclosed
EP-1315727-B1 7-OXO PYRIDOPYRIMIDINES HOFFMANN LA ROCHE (CH) 2005-06-29 — — EP disclosed
US-20040192709-A1 7-oxo-pyridopyrimidines (II) SYNTEX (U.S.A.) LLC 2004-09-30 — — US disclosed
US-6753427-B2 2,6-DISUBSTITUTED 7-OXOPYRIDO(2,3-D)PYRIMIDINES; INHIBITORS OF PROTEIN KINASES; TREATING DISEASES MEDIATED BY THE PRO-INFLAMMATORY CYTOKINES, E.G., TUMOR NECROSIS FACTOR, INTER-LEUKINS, CYCLOXYGENASE; CHRONIC OBSTRUCTIVE PULMONARY DISEASE SYNTEX (U.S.A.) LLC 2004-06-22 — — US disclosed
US-20030144307-A1 7-oxo-pyridopyrimidines (II) ARZENO HUMBERTO BARTOLOME (US) 2003-07-31 — — US disclosed
EP-1315727-A2 7-OXO PYRIDOPYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2003-06-04 — — EP disclosed
US-6518276-B2 Treating a p38 mediated disorders SYNTEX (U.S.A.) LLC 2003-02-11 — — US disclosed
US-20020055513-A1 7-oxo-pyridopyrimidines (II) SYNTEX (U.S.A.) LLC 2002-05-09 — — US disclosed
WO-2002018379-A2 7-OXO PYRIDOPYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2002-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144307-A1 7-oxo-pyridopyrimidines (II) AR, CYP3A7, CYP2F1 HTT 3370/4885HSD17B10 1332/4885ALDH1A1 98/4885
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 HTT 3632/4885HSD17B10 255/4885ALDH1A1 2353/4885
US-20020055513-A1 7-oxo-pyridopyrimidines (II) AR, CYP3A7, CYP2F1 HTT 3370/4885HSD17B10 1332/4885ALDH1A1 98/4885
US-20230240960-A1 COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT CUTA, COL14A1, DSG1 HTT 770/4885HSD17B10 1445/4885ALDH1A1 3302/4885
US-20230278989-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM MDM2, TP53, TP53BP1 HTT 351/4885HSD17B10 1931/4885ALDH1A1 192/4885
US-20040192709-A1 7-oxo-pyridopyrimidines (II) AR, CYP3A7, CYP2F1 HTT 3370/4885HSD17B10 1332/4885ALDH1A1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.